Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Dose-Finding, Placebo Controlled, Phase II Multicenter Study of Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

NCT01655823 is registered in ClinicalTrials.gov with Wex Pharmaceuticals Inc. as lead sponsor.

NCT NCT01655823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01655823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Dose-Finding, Placebo Controlled, Phase II Multicenter Study of Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Lead sponsor
Wex Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2012
Completion date
February 11, 2015
Enrollment
125 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic pain, pain, peripheral neuropathy